passionate about laboratory testing, roses and the beach. my opinions are my own.
Joined August 2014
- Tweets1.8K
- Following191
- Followers343
- Likes1.9K
Proud of our team
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the @AMPath, @TheACMG, @cpicpgx, @Pathologists, @KNMP, ESPT, @pharmgkb, and @PharmVar.
jmdjournal.org/article/S1525…
vicky pratt retweeted
DUE THURSDAY: Your colleagues at #AMPath24 want to hear about your unique, interesting, and/or challenging case studies! Early Bird Case Study submissions are due September 5: ow.ly/hE4c50SEnbF.
We hope to hear from you in Vancouver!
#molpath #pathologists
vicky pratt retweeted
Representing @Pathologists as cochair for the upcoming #MolPath guidelines for #lungcancer has been the honor of my academic career 🙏🏽 Make your voice heard during Open Comment Period 🔊 @AMPath @IASLC
clinicallab.com/internationa…
vicky pratt retweeted
AMP has filed a lawsuit against the FDA to challenge the final rule on LDTs. AMP stands firm in its commitment to ensuring that regulations enhance patient care without stifling innovation. More Info: ow.ly/Y6ar50T21SP
#MolPath #LDTs #FDARegulation #PatientCare #CLIAMod
vicky pratt retweeted
AMP is honored to announce the recipients of its 2024 Recognition Awards, which will be presented at #AMPath24 in Vancouver this November. Congratulations to Dr. Atul Butte, Dr. Ronald Przygodzki, and Dr. Eric Konnick!
Read the full press release: ow.ly/LVAH50SUf9u
Proud of this group and excited to see our latest recommendations in press.
AMP PGx WG w/ ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, & PharmVar have released updated DPYD genotyping recs, emphasizing the importance of variant inclusion in clinical tests. Learn more: ow.ly/hihK50SHvLR #PGxTesting #MolPath #Pharmacogenomics
Excited to see our workgroup manuscript in press. Proud of our team @AMPath @cpicpgx @PharmVar @pharmgkb @Pathologists @TheACMG
AMP, ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, & PharmVar’s latest consensus guideline helps design clinical DPYD genotyping assays, to help identify individuals at risk for severe fluoropyrimidine toxicity. Click to Read: ow.ly/aGq150SHvCU #PGxTesting
vicky pratt retweeted
AMP’s PGx WG with ACMG, CPIC, CAP, DPWG, ESPT, PharmGKB, & PharmVar have published new recommendations to standardize DPYD genotyping assays, to enhance patient care & testing consistency across labs. Read more here: ow.ly/trAk50SHvrv #Pharmacogenomics
Join @NASEM_Health on 7/17 for a hybrid workshop on sustaining community engagement in #GenomicsResearch. Register to learn about possible solutions to obstacles to sustained & equitable #CommunityEngagement in genomics: ow.ly/rMrA50RZ4u8 #GenomicsRT #CommunityPartnership
vicky pratt retweeted
Excited to host the #CLINPGX2024 meeting with @UPennIBI @pharmgkb and @cpicpgx. We have an exciting meeting planned for the next two days. Thanks to all who traveled to @PennMedicine for the meeting to discuss clinical implementation of pharmacogenomics.
vicky pratt retweeted
Great opening to #CLINPGX2024 by @drkellycaudle! Looking forward to a great meeting!
vicky pratt retweeted
Include a #GraphicalAbstract with your next submission to @JMDiagn! Promote understanding in a simple panel that is readily sharable on social media for increased views, downloads and citations.
Submission to JMD is free: editorialmanager.com/jmdi/de…
vicky pratt retweeted
AMP is disappointed the FDA decided to release its Final Rule on Laboratory Developed Tests. While we take time to assess the rule's impact on our members and their patients, you can learn about AMP’s long-held position on LDT oversight at: amp.org/LDT
vicky pratt retweeted
New #Spotlight: 2024 Updates to American Medical Association’s Current Procedural Terminology Codes for Oncology Panel Testing. From @AMPath member and @JMDiagn Associate Editor @prattvm1.
jmdjournal.org/article/S1525…
vicky pratt retweeted
FANTASTIC testimony by Dr. Dara Aisner on the potential impact of the FDA proposed ruling for LDT in today’s Health Subcommittee Hearing on Regulation of Diagnostic Tests ! Thank you @AMPath staff as well… I c u🫶🏽! Replay here 👉🏽 m.youtube.com/@energyandcomm…
vicky pratt retweeted
Prenatal testing for variants in genes associated with hereditary cancer risk: laboratory experience and considerations. Authors from @LabCorp.
Full #OpenAccess text: jmdjournal.org/article/S1525…
vicky pratt retweeted
Weekly Resource Spotlight: Interested in Pharmacogenomics? The AMP "Molecular in My Pocket" guide is a must-have. And it's FREE! Grab your copy now: ow.ly/JMlY50QAEGi #molpath #pathologists #PathX
vicky pratt retweeted
Check out our latest publication on methylation array in @JMDiagn! We hope it would serve as a useful resource to our peers in the clinical genomic field. @AMPath doi.org/10.1016/j.jmoldx.202…
vicky pratt retweeted
Need a quick reference guide on Ovarian Cancer Molecular Biomarkers? Check out these new cards produced by the AMP Training and Education Committee: ow.ly/un6J50QoUoJ #molpath #PathX
